MedTrace Logo

Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

NCT00306384 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3323

Last updated 2013-03-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Alogliptin

Alogliptin tablets.

Sponsors & Collaborators

Principal Investigators

  • VP Biological Sciences · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States
  • Argentina
  • Brazil
  • Chile
  • Czechia
  • Dominican Republic
  • Germany
  • Guatemala
  • Netherlands
  • Peru
  • Poland
  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306384 on ClinicalTrials.gov